Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2019-11-07 Capital/Financing Update
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans or inducement awards. It includes details about the registration of 375,000 shares of common stock related to inducement stock option awards. The document references incorporation by reference of other filings such as 10-K, 10-Q, and proxy statements but itself is a registration statement for securities issuance, not a financial report or earnings release. It is not an Annual Report, Earnings Release, or any other financial or governance report. Therefore, it fits the category of a Capital/Financing Update as it relates to securities registration and issuance under the Securities Act of 1933.
2019-11-07 English
10-Q
Interim / Quarterly Report Q3 2019
2019-11-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2019, by Zafgen, Inc. It announces the company's financial results for the third quarter of 2019 and includes a press release as an exhibit. The text explicitly states that the press release is being furnished and incorporated by reference, and the document itself is a current report rather than the full financial report. The length is 3436 characters, which is relatively short and consistent with an earnings release announcement rather than a full quarterly report. The key phrase 'announced its financial results for the third quarter' and the inclusion of a press release as an exhibit strongly indicate this is an Earnings Release (ER) filing. It is not a full Interim/Quarterly Report (IR) because it does not contain substantive financial statements or detailed analysis, only a summary announcement and a press release. Therefore, the correct classification is Earnings Release (ER).
2019-11-06 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-10-15 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-10-10 English
8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 17, 2019, by Zafgen, Inc. The key content is a notice from Nasdaq regarding the company's failure to meet the minimum bid price requirement for continued listing on the Nasdaq Global Market. It details the compliance period and potential consequences including transfer to Nasdaq Capital Market or delisting. This is a regulatory announcement about the company's listing status, specifically a delisting notice or warning. The document is not a full financial report, earnings release, or management discussion, but an official notice about potential delisting. Therefore, the appropriate classification is Delisting Announcement (DLST).
2019-09-19 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.